Personalized immune cells engineered to fight tough ovarian cancer
NCT ID NCT07030907
Summary
This early-stage trial is testing a new personalized cell therapy called OPB-101 for women with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. Doctors will modify a patient's own immune cells in a lab to target the cancer and then infuse them back in a one-time treatment. The main goals are to find a safe dose and see if the therapy shows early signs of helping control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Roswell Park
RECRUITINGBuffalo, New York, 14203, United States
Contact
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.